Education
About Us
Working with TipRanks
Follow Us
Acurx Pharmaceuticals Llc (ACXP)
:ACXP
ACXP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.40 - $3.33
Previous CloseN/A
Volume243.54K
Average Volume (3M)378.20K
Market Cap
$9.00M
Enterprise Value$25.33M
Total Cash (Recent Filing)-$2.48M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.27
Next Earnings
May 08, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding22,042,511
10 Day Avg. Volume162,837
30 Day Avg. Volume378,197
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.19
Forecast
1Y Price Target
$6.17Price Target Upside1404.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Acurx Pharmaceuticals News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessIbezapolstat's efficacy was impressive in two Phase 2 trials, demonstrating a pooled clinical cure rate of 96%.
Regulatory ProgressReceived positive regulatory guidance from EU regulators for P3.
Safety ProfileIbezapolstat was safe and well-tolerated, with no drug-related withdrawals or serious adverse events occurring.
Bears Say
Financial ChallengesThere needs to be a substantial capital raise and/or other funding resources to initiate a P3 program.
Investment RisksRisks to the investment thesis and target price include failure or equivocal data in the Phase 3 trials of ibezapolstat.
Regulatory Approval RiskFailure to secure regulatory approval of ibezapolstat.
---
Ownership Overview
10.94% Insiders
3.02% Mutual Funds
1.80% Other Institutional Investors
81.66% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ACXP FAQ
What was Acurx Pharmaceuticals Llc’s price range in the past 12 months?
Acurx Pharmaceuticals Llc lowest stock price was $0.40 and its highest was $3.33 in the past 12 months.
What is Acurx Pharmaceuticals Llc’s market cap?
Acurx Pharmaceuticals Llc’s market cap is $9.00M.
When is Acurx Pharmaceuticals Llc’s upcoming earnings report date?
Acurx Pharmaceuticals Llc’s upcoming earnings report date is May 08, 2025 which is in 38 days.
How were Acurx Pharmaceuticals Llc’s earnings last quarter?
Acurx Pharmaceuticals Llc released its earnings results on Mar 18, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.175 by $0.015.
Is Acurx Pharmaceuticals Llc overvalued?
According to Wall Street analysts Acurx Pharmaceuticals Llc’s price is currently Undervalued.
Does Acurx Pharmaceuticals Llc pay dividends?
Acurx Pharmaceuticals Llc does not currently pay dividends.
What is Acurx Pharmaceuticals Llc’s EPS estimate?
Acurx Pharmaceuticals Llc’s EPS estimate is -0.13.
How many shares outstanding does Acurx Pharmaceuticals Llc have?
Acurx Pharmaceuticals Llc has 22,042,511 shares outstanding.
What happened to Acurx Pharmaceuticals Llc’s price movement after its last earnings report?
Acurx Pharmaceuticals Llc reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.175. Following the earnings report the stock price went down -14.894%.
Which hedge fund is a major shareholder of Acurx Pharmaceuticals Llc?
Currently, no hedge funds are holding shares in ACXP
---
Company Description
Acurx Pharmaceuticals Llc
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
---
ACXP Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a generally positive outlook for Acurx Pharmaceuticals, highlighted by significant clinical advancements and regulatory support for its lead candidate, ibezapolstat. Despite financial challenges and the need for additional funding, the company has made meaningful progress in reducing its losses and securing a new patent. Management remains confident in addressing potential NASDAQ listing concerns.Read More>---
ACXP Stock 12 Month Forecast
Average Price Target
$6.17
▲(1404.88% Upside)
Technical Analysis
Best Analysts Covering ACXP
1 Year
1 Year Success Rate
4/19 ratings generated profit
1 Year Average Return
-36.74%
reiterated a buy rating 11 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 21.05% of your transactions generating a profit, with an average return of -36.74% per trade.
---